Under construction – not a live service
Sign in
Taking people in TürkiyePhase 3

Tests deucravacitinib in children with juvenile psoriatic arthritis

Tests deucravacitinib against placebo in children aged 5 to 17 with juvenile psoriatic arthritis.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Ankara, Istanbul, and İstanbul - Fatih, TürkiyeSee the 4 sitesAlso in 10 other countries, 42 sites
Trial code
Registry title
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Status
Recruiting
Phase
Phase 3
People taking part
60 people, planned
Started
13 Mar 2025
Expected to end
4 Mar 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Deucravacitinib
  • Placebo
Record updated
6 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teenagers aged 5 to 17 who have active juvenile psoriatic arthritis (JPsA, a type of arthritis in young people that goes with psoriasis).

Age
5 to 17 years
Sex
All sexes can join.
Disease stage
Diagnosed with juvenile psoriatic arthritis (JPsA), with at least three joints affected by arthritis.
Earlier treatment
Must have tried at least one type of medicine for JPsA for at least three months, but it did not work well or caused problems.

Main reasons for not taking part

  • Diagnosed with JPsA before 5 years of age
  • Other types of juvenile idiopathic arthritis (JIA) that are not JPsA
  • History of chronic eye inflammation (uveitis)
  • Uveitis diagnosed within the last three months

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA)
  • Participants must have at least three joints that are affected by arthritis
  • Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems

Who cannot take part

  • Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months
  • Participants must not have been diagnosed with JPsA before 5 years of age
  • Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
  • Other protocol-defined Inclusion/Exclusion criteria apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 5 and 17 years old?

Where in Türkiye

Also in 10 other countries, 42 sites

  • AnkaraHospital not named in the registryContact: Site 0044Not yet recruiting
  • AnkaraHospital not named in the registryContact: Site 0061Not yet recruiting
  • Ümraniye Training and Research HospitalIstanbul, TürkiyeContact: Betul Sozeri, Site 0045Taking people
  • Istanbul Universitesi Cerrahpasaİstanbul - Fatih, TürkiyeContact: Ozgur Kasapcopur, Site 0043Taking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

The 2 groups in the trial

  • Arm ATreatment being tested

    Treatment: Deucravacitinib

  • Arm BPlacebo, for comparison

    Treatment: Deucravacitinib and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis
Plain-language title
Tests deucravacitinib in children with juvenile psoriatic arthritisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06869551, who can take part
Record updated
6 October 2026
Under construction, not live – A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis (NCT06869551) – Frontlight Research